Cynomolgus macaques immunized with two HIV-1 Tat stabilized proteins raise strong and long-lasting immune responses with a pattern of Th1/Th2 response differing from that in mice

Vaccine

Volumn 27, Issue 39, 2009, Pages 5349-5356

  Turbant, Sabrina ^a   Martinon, Frédéric ^b   Moine, Gervaise ^a   Le Grand, Roger ^b   Léonetti, Michel ^a  

^a DIF   (France)

^b INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

Author keywords

HIV 1; Immune response; Immunogen; Sulfated polysaccharide; Th1 Th2 response; Transcriptional transactivator

Indexed keywords

ALUMINUM POTASSIUM SULFATE; GAMMA INTERFERON; TAT 101; TAT 101SF162; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MACACA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STABILITY; TH1 CELL; TH2 CELL;

AIDS VACCINES; ANIMALS; EPITOPE MAPPING; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; IMMUNITY, CELLULAR; INTERFERON-GAMMA; MACACA FASCICULARIS; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; NEUTRALIZATION TESTS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TH1 CELLS; TH2 CELLS;

EID: 68449094197     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.06.083     Document Type: Article

References (28)

1. Reiss P., Lange J.M., and de Ronde A. Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1. J Med Virol 30 3 (1990) 163-168
2. Re M.C., Furlini G., and Vignoli M. Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo. J Acquir Immune Defic Syndr Hum Retrovirol 10 4 (1995) 408-416
3. Re M.C., Vignoli M., and Furlini G. Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients. J Clin Virol 21 1 (2001) 81-89
4. Zagury J.F., Sill A., and Blattner W. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine. J Hum Virol 1 4 (1998) 282-292
5. Richardson M.W., Mirchandani J., and Duong J. Antibodies to Tat and Vpr in the GRIV cohort: differential association with maintenance of long-term non-progression status in HIV-1 infection. Biomed Pharmacother 57 1 (2003) 4-14
6. Froebel K.S., Aldhous M.C., Mok J.Y., Hayley J., Arnott M., Peutherer J.F., and Cytotoxic. T lymphocyte activity in children infected with HIV. AIDS Res Hum Retroviruses 10 Suppl. 2 (1994) S83-88
7. van Baalen C.A., Pontesilli O., and Huisman R.C. Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J Gen Virol 78 Pt 8 (1997) 1913-1918
8. Cafaro A., Caputo A., and Fracasso C. Control of SHIV-89,6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat Med 5 6 (1999) 643-650
9. Cafaro A., Titti F., and Fracasso C. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). Vaccine 19 20-22 (2001) 2862-2877
10. Osterhaus A.D., van Baalen C.A., and Gruters R.A. Vaccination with Rev and Tat against AIDS. Vaccine 17 20-21 (1999) 2713-2714
11. Pauza C.D., Trivedi P., and Wallace M. Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques. Proc Natl Acad Sci USA 97 7 (2000) 3515-3519
12. Silvera P., Richardson M.W., and Greenhouse J. Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein. J Virol 76 8 (2002) 3800-3809
13. Allen T.M., Mortara L., and Mothe B.R. Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication. J Virol 76 8 (2002) 4108-4112
14. Lecoq A., Moine G., and Bellanger L. Increasing the humoral immunogenic properties of the HIV-1 Tat protein using a ligand-stabilizing strategy. Vaccine 26 21 (2008) 2615-2626
15. Rusnati M., Tulipano G., and Urbinati C. The basic domain in HIV-1 Tat protein as a target for polysulfonated heparin-mimicking extracellular Tat antagonists. J Biol Chem 273 26 (1998) 16027-16037
16. Rusnati M., Tulipano G., and Spillmann D. Multiple interactions of HIV-I Tat protein with size-defined heparin oligosaccharides. J Biol Chem 274 40 (1999) 28198-28205
17. Smith S.M., Pentlicky S., and Klase Z. An in vivo replication-important function in the second coding exon of Tat is constrained against mutation despite cytotoxic T lymphocyte selection. J Biol Chem 278 45 (2003) 44816-44825
18. Groenink M., Fouchier R.A., and de Goede R.E. Phenotypic heterogeneity in a panel of infectious molecular human immunodeficiency virus type 1 clones derived from a single individual. J Virol 65 4 (1991) 1968-1975
19. Kittiworakarn J., Lecoq A., and Moine G. HIV-1 Tat raises an adjuvant-free humoral immune response controlled by its core region and its ability to form cysteine-mediated oligomers. J Biol Chem 281 6 (2006) 3105-3115
20. Harouse J.M., Gettie A., Tan R.C., Blanchard J., and Cheng-Mayer C. Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science 284 5415 (1999) 816-819
21. Harouse J.M., Gettie A., and Eshetu T. Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3). J Virol 75 4 (2001) 1990-1995
22. DeKruyff R.H., Fang Y., and Umetsu D.T. IL-4 synthesis by in vivo primed keyhole limpet hemocyanin-specific CD4+ T cells: I. Influence of antigen concentration and antigen-presenting cell type. J Immunol 149 11 (1992) 3468-3476
23. Gieni R.S., Fang Y., Trinchieri G., Umetsu D.T., and DeKruyff R.H. Differential production of IL-12 in BALB/c and DBA/2 mice controls IL-4 versus IFN-gamma synthesis in primed CD4 lymphocytes. Int Immunol 8 10 (1996) 1511-1520
24. Marechal V., Clavel F., Heard J.M., and Schwartz O. Cytosolic Gag p24 as an index of productive entry of human immunodeficiency virus type 1. J Virol 72 3 (1998) 2208-2212
25. Lindblad E.B. Aluminium compounds for use in vaccines. Immunol Cell Biol 82 5 (2004) 497-505
26. Shen L., and Rock K.L. Priming of T cells by exogenous antigen cross-presented on MHC class I molecules. Curr Opin Immunol 18 1 (2006) 85-91
27. Lin M.L., Zhan Y., Villadangos J.A., and Lew A.M. The cell biology of cross-presentation and the role of dendritic cell subsets. Immunol Cell Biol 86 4 (2008) 353-362
28. Fanales-Belasio E., Moretti S., and Fiorelli V. HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection. J Immunol 182 5 (2009) 2888-2897